Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : KT07,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase I Pharmacokinetics Study for KT07 Capsule
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 04, 2022
Lead Product(s) : KT07,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Yiling Pharmaceutical's Patent Depression-resolving Drug Approved for Marketing in China
Details : According to the decreased values for main efficacy indicators of the Hamilton Depression Scale scores from the baseline, the efficacy of the test group was better than that of the placebo group, and also not inferior to that of the fluoxetine hydrochlor...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 22, 2021
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lianhua Qingwen,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Recipient : Xiamen University
Deal Size : Inapplicable
Deal Type : Inapplicable
New Progress in Study on Mechanism of Lianhua Qingwen Capsules for Treatment of COVID-19
Details : The study result, "Screening of the Anti-COVID-19 Pharmacological Active Ingredients of Traditional Chinese Medicine Lianhua Qingwen Capsules (KT07) Based on Human Exposure and ACE2 Biochromatography", was published in the top journal of pharmacology.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 26, 2021
Lead Product(s) : Lianhua Qingwen,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : Xiamen University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lisinopril,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Preparation Products of Yiling Pharma Approved by FDA for Launch in the US Market
Details : The announcement showed that Lisinopril Tablets are mainly used for the treatment of essential hypertension (EH) and renal vascular hypertension (RVH) and were originally researched and developed by Astrazeneca and approved for launch in the United State...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 19, 2020
Lead Product(s) : Lisinopril,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lianhua Qingwen,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lianhua Qingwen Receives First International Approval for Covid-19 Treatment
Details : Lianhua Qingwen Capsules was approved to be registered as a drug to treat symptoms like fever, cough, debilitation, sore muscles, nasal obstruction, runny nose, headaches, a dry and sore throat, shortness of breath, and a red tongue caused by viral disea...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 09, 2020
Lead Product(s) : Lianhua Qingwen,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Clinical Study Trial of Phenlarmide in China
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 15, 2019
A Single-dose Study to Investigate the Tolerance and Pharmacokinetics of Finamine Tablets in China
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 14, 2019
Lead Product(s) : Felbinac Trometamol,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase I Clinical Study Trial of Felbinac Trometamol Injection in China
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 01, 2017
Lead Product(s) : Felbinac Trometamol,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KT07,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Clinical Trial of KT07 Capsule in the U.S.A
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 15, 2016
Lead Product(s) : KT07,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
